Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.55 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26974375 | 0.89 | MAPT (0.72) | MAPTPIK3CGSIRT1POLBTDP1 | |
| SCHEMBL26034335 | 0.88 | MAPT (0.57) | MAPTPIK3CGSIRT1SPHK2SPHK1 | |
| SCHEMBL26974386 | 0.86 | PIK3CG (0.60) | MAPTPIK3CGSIRT1POLBTDP1 | |
| SCHEMBL683909 | 0.86 | PIK3CG (0.66) | MAPTPIK3CGSIRT1NPC1RAB9A | |
| SCHEMBL26034338 | 0.86 | MAPT (0.55) | MAPTSPHK2SPHK1TDP1NPC1 | |
| SCHEMBL21211496 | 0.86 | KMT2A (0.71) | SIRT1POLBNPC1RAB9AKMT2A | |
| SCHEMBL12387760 | 0.86 | KMT2A (0.71) | SIRT1POLBNPC1RAB9AKMT2A | |
| SCHEMBL15127234 | 0.85 | PIK3CG (0.61) | MAPTPIK3CGSIRT1POLBTDP1 | |
| SCHEMBL15127223 | 0.84 | POLB (0.68) | MAPTPIK3CGSIRT1POLBTDP1 | |
| SCHEMBL26974360 | 0.84 | KDM1A (0.67) | MAPTPIK3CGSIRT1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018169-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | UNIV YALE (US) | 2024-01-18 | — | — | US | disclosed |
| US-11739104-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739104-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | MAPT 3943/4885PIK3CG 1908/4885SIRT1 3788/4885 |
| US-20240018169-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROUP II INTRON RNA | NSUN2, RBM22, RNGTT | MAPT 3943/4885PIK3CG 1908/4885SIRT1 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.